Assessment of Gabapentin effect in patients undergoing laparoscopic urology surgery

Phase 3

• Conditions: laparoscopic urology.; Urological procedure associated with injury or harm in therapeutic use; PK80.6

• Registration Number: IRCT20180625040232N9
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Patients candidate for laparoscopic urology
Age between 18 and 65 years
Patients with physical status one and two according to the criteria of the American Anesthesia Association (ASA I, II)

Exclusion Criteria

Having any coagulopathy
Opium addiction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain. Timepoint: 6, 24, 12 and 48 hours after surgery. Method of measurement: Visual analogue scale (VAS).;Nausea and vomiting. Timepoint: 6, 24, 12 and 48 hours after surgery. Method of measurement: Post operative nausea and vomiting scale (PONV scale).

Secondary Outcome Measures

Name	Time	Method
Dosage of analgesic. Timepoint: Up to 48 hours after surgery. Method of measurement: milligram.;Receiving anti-nausea and vomiting medicine. Timepoint: Up to 48 hours after surgery. Method of measurement: yes/ no.